What one share of Protalix BioTherapeutics holds
We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension.
Protalix BioTherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.99 |
|---|---|
| Profit | $0.23 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | $0.09 |
| Cash and investments | $0.34 |
| Book value | $0.89 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | $0.82 | −$3.58 | $0.97 | −$5.72 | — | −$1.39 |
| 2011 | $0.99 | −$4.32 | $0.67 | −$3.46 | — | −$3.05 |
| 2012 | $3.84 | −$1.28 | $0.23 | −$0.16 | — | −$0.36 |
| 2013 | $0.00 | −$3.01 | $0.20 | −$3.52 | — | −$2.88 |
| 2014 | $0.38 | −$3.22 | $0.08 | −$3.24 | — | −$5.94 |
| 2015 | $0.46 | $6.11 | $0.05 | −$2.61 | — | $1.09 |
| 2016 | $0.91 | −$2.90 | $0.08 | −$3.25 | — | −$0.80 |
| 2017 | $1.61 | −$6.37 | $0.07 | −$0.84 | — | −$2.05 |
| 2018 | $2.33 | −$1.80 | $0.05 | −$0.57 | — | −$3.56 |
| 2019 | $3.69 | −$1.23 | $0.04 | −$1.35 | — | −$4.74 |
| 2020 | $2.16 | −$0.22 | $0.02 | −$0.92 | — | −$0.78 |
| 2021 | $0.87 | −$0.62 | $0.03 | −$0.27 | — | −$0.13 |
| 2022 | $0.98 | −$0.31 | $0.01 | −$0.53 | — | −$0.20 |
| 2023 | $0.79 | $0.09 | $0.01 | −$0.03 | — | $0.46 |
| 2024 | $0.66 | $0.04 | $0.02 | $0.09 | — | $0.57 |
| 2025 | $0.67 | −$0.08 | $0.02 | −$0.17 | — | $0.60 |
Common questions about Protalix BioTherapeutics
How much does one share of Protalix BioTherapeutics earn?
Over the last 12 months, each share of Protalix BioTherapeutics earned $0.23 of profit on $0.99 of sales, keeping about 24¢ of every $1 (profit margin).
Does Protalix BioTherapeutics pay a dividend?
Protalix BioTherapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Protalix BioTherapeutics’s book value per share?
Protalix BioTherapeutics’s book value is $0.89 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Protalix BioTherapeutics have?
Each share of Protalix BioTherapeutics has $0.34 of cash and investments, as of June 30, 2026.
What is Protalix BioTherapeutics’s free cash flow per share?
$0.09 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Protalix BioTherapeutics bought back shares?
Protalix BioTherapeutics’s share count rose about 870% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.